Acute Measles Panel, IgM Antibody and PCR

CPT: 86765; 87798

To be determined. Updates will be made when available.

86765; 87798

Updated on 11/15/2024

Synonyms

Rubeola


Test Includes

Measles (Rubeola) Antibodies, IgM and Measles (Rubeola), PCR, Swab


Specimen Requirements


Specimen

Serum and throat or NP swab


Volume

1 mL serum and 1 swab


Minimum Volume

0.5 mL serum and 1 swab (Note: This volume does not allow for repeat testing.)


Container

Serum: gel-barrier tube, red-top tube or transfer tube

Swab: Viral Transport Media (VTM) or Universal Transport Media (UTM)


Collection

Serum: If tube other than a gel-barrier tube is used, transfer serum to a plastic transport tube.

Swab: Throat specimen (preferred): Collect the specimen by swabbing the posterior pharynx. Nasopharyngeal swab: Collect the NP swab using standard techniques.


Storage Instructions

Refrigerate.


Stability Requirements

Temperature Period
Room temperatureUnstable
Refrigerated

Serum: 7 days

Swab: 7 days

Frozen

Serum: 6 months

Swab: 14 days


Causes for Rejection

Improperly submitted specimens; grossly hemolyzed, lipemic and icteric samples; heat-inactivated samples; samples with visible particulate matter or gross bacterial contamination; specimen not received in an approved VTM/UTM; swabs received in Liquid Amies (E-Swabs) or other bacterial swabs; specimens received without a swab; grossly leaking specimens; specimens received outside the stated stability


Test Details


Use

This test is used as a guideline-aligned laboratory diagnosis of acute measles virus infection in patients presenting with febrile rash illness and clinically compatible measles symptoms.


Limitations

A negative test does not rule out infection with measles virus. Results should be interpreted in conjunction with clinical finding.

The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings.

Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease. Specimens should be collected as soon as possible after the development of rash to maximize the sensitivity of measles RNA detection.

Improperly collected samples may result in false negative results.

PCR assays may be impacted by viral variants and may result in reduced sensitivity or false negative results.

The Measles PCR was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

A negative test does not rule out infection with measles virus. Results should be interpreted in conjunction with clinical finding.

The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings.

Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease. Specimens should be collected as soon as possible after the development of rash to maximize the sensitivity of measles RNA detection.

Improperly collected samples may result in false negative results.

PCR assays may be impacted by viral variants and may result in reduced sensitivity or false negative results.

The Measles PCR was developed and its performance characteristics determined by Labcorp. It has not been been cleared or approved by the Food and Drug Administration. been cleared or approved by the Food and Drug Administration.

A negative test does not rule out infection with measles virus. Results should be interpreted in conjunction with clinical finding.

The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings.

Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease. Specimens should be collected as soon as possible after the development of rash to maximize the sensitivity of measles RNA detection.

Improperly collected samples may result in false negative results.

PCR assays may be impacted by viral variants and may result in reduced sensitivity or false negative results.

The Measles PCR was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administratio been cleared or approved by the Food and Drug Administration.


Methodology

Chemiluminescence immunoassay (CLIA) and Polymerase Chain Reaction (PCR)


References

Clinical Overview of Measles. Centers for Disease Control and Prevention website: https://www.cdc.gov/measles/hcp/clinical-overview/index.html#cdc_clinical_overview_test_dia-diagnosis-and-laboratory-testing. Updated July 15, 2024. Accessed October 2024.

Clinical Overview of Measels. Centers for Disease Control and Prevention website: https://www.cdc.gov/measles/hcp/clinical-overview/index.html#cdc_clinical_overview_test_dia-diagnosis-and-laboratory-testing. Updated July 15, 2024. Accessed October 2024.

Clinical Overview of Measles. Centers for Disease Control and Prevention website: https://www.cdc.gov/measles/hcp/clinical-overview/index.html#cdc_clinical_overview_test_dia-diagnosis-and-laboratory-testing. Updated July 15, 2024. Accessed October 2024.


For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf